Cerebral Infarction Drugs Market Segmentation:
Distribution Channel Segment Analysis
The cerebral infarction drugs market is segmented and analyzed for demand and supply by distribution channel into hospitals, drug stores, online pharmacies, and others. Out of these four segments, the hospitals segment is estimated to gain the largest market share of about 56% in the year 2035. The growth of the segment can be attributed to the worldwide surging patient pool in hospitals to get efficient treatment and drugs for cerebrovascular disease, and ischemic strokes. For instance, in France, around 98,450 people were hospitalized for ischemic strokes and around 19,898 for intracerebral hemorrhage in 2019. In addition to this, the radically rising prevalence of the cerebrovascular disease among people, coupled with increasing stances of ischemic strokes are also estimated to boost the segment growth throughout the forecast period.
Drug Class Segment Analysis
The cerebral infarction drugs market is also segmented and analyzed for demand and supply by drug class into tissue plasminogen activators (tPA), anticoagulants, and others. Amongst these three segments, the tissue plasminogen activators (tPA) segment is expected to garner a significant share of around 65% in the year 2035. The growth of the segment can be credited to the effectiveness of the tissue plasminogen activators (tPA) drugs in the treatment of cerebral infarction, and ischemic strokes, followed by its efficiency to restore blood flow by dissolving the clots in a blood vessel by activating the conversion of plasminogen to plasmin, an enzyme accountable for the breakdown of clots. On the other hand, the anticoagulants segment is projected to witness a notable CAGR during the forecast period, owing to their effectiveness as anticoagulants reduce the risk of an ischemic stroke or other embolic occurrences by more than two-thirds. Moreover, the surge in novel anticoagulant development is another factor anticipated to drive the growth of the market. For instance, Warfarin and some other newer anticoagulants function equally well in the long-term therapy of venous thromboembolism to avoid blood clots. One clot is avoided for every 15 persons who take any anticoagulant.
Our in-depth analysis of the global market includes the following segments:
|
By Diagnosis |
|
|
By Drug Class |
|
|
By Distribution Channel |
|
